Rain Therapeutics (NASDAQ:RAIN) reported quarterly losses of $(0.68) per share which met the analyst consensus estimate. This is a 2.86 percent increase over losses of $(0.70) per share from the same period last year.
Top 5 Industrials Stocks That Could Lead To Your Biggest Gains In February
The most oversold stocks in the industrials sector presents an opportunity to buy into undervalued companies.
